Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
You may also be interested in...
Finance Watch: SPAC Deals Emerge As IPO Market Goes Quiet Again
Public Company Edition: Direct Biologics, YishengBio and Estrella Biopharma will go public by merging with special purpose acquisition corporations. Also, Vir lands a government contract worth up to $1bn, Idorsia raises CHF164m ($167.4m) in a real estate deal and Adamis reviews alternatives.
As Jounce’s Vopratelimab Fails, Door Opens For LILRB2 Inhibitor JTX-8064
Vopratelimab is the second major ICOS agonist program to fail since GSK halted studies of feladilimab last year, but an analyst pinned higher hopes on JTX-8064.
BMS Is Latest To Join Synthetic Lethality Bandwagon With Volastra Deal
Deal Snapshot: The drug maker is betting $30m up front and up to $1.1bn in milestone fees for an increasingly popular approach to oncology drug development.